277 related articles for article (PubMed ID: 20684321)
1. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
[TBL] [Abstract][Full Text] [Related]
2. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
3. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
4. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
5. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
[TBL] [Abstract][Full Text] [Related]
6. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].
Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
8. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
10. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
[TBL] [Abstract][Full Text] [Related]
11. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
12. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
13. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
14. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
15. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
16. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
Brassell SA; Kao TC; Sun L; Moul JW
Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
[TBL] [Abstract][Full Text] [Related]
18. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
20. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
